UBS Adjusts InnoCare Pharma’s Price Target to HK$16.20 From HK$17.70, Keeps at Buy
UBS Adjusts InnoCare Pharma’s Price Target to HK$16.20 From HK$17.70, Keeps at Buy
瑞銀將諾誠健華的目標股價從17.70港元調整至16.20港元,維持買入
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊